Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of initial trials using dendritic cell transformation by end of 2026?
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%
Clinical trial results published in scientific journals
Penn State Researchers Enhance NK Cells to Target Solid Tumors; Science Study Reveals Dendritic Cell Transformation
Oct 27, 2024, 05:34 AM
Researchers from Penn State Hershey have developed a method to enhance immune cells' ability to target solid tumors. By creating a light-activated switch that controls the protein septin-7, the team incorporated this innovation into natural killer (NK) cells, allowing them to penetrate and kill tumor cells grown in laboratory settings. Additionally, a study published in Science reveals that cancer cells can be reprogrammed in vivo into dendritic cells, which can activate T cells and promote antitumor immunity. This transformation utilizes transcription factors such as PU.1, IRF8, and BATF3, enabling the modified cells to present antigens and stimulate cancer-specific T cell responses. Furthermore, researchers at the Wyss Institute have developed a metabolic labeling technology that enhances T cells' persistence in solid tumors by attaching immune-boosting cytokines directly to them, thereby improving their cancer-fighting capabilities.
View original story
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Significant survival improvement • 25%
Partial survival improvement • 25%
No significant change • 25%
Deterioration • 25%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Widely adopted in clinical settings • 25%
Other • 25%
Not adopted • 25%
Limited adoption in research settings • 25%